Tag: Patent expiration

ARIKAYCE (amikacin liposome inhalation suspension) was first approved by the FDA on September 28, 2018 [1.2.5]. Currently, **is there a generic for ARIKAYCE?** No, ARIKAYCE is only available as a brand-name medication and does not have a generic version [1.2.1, 1.3.4].

A 30-day supply of the brand-name prescription drug Glyxambi can cost hundreds of dollars without insurance, as there is currently no lower-priced generic version available in the United States. This raises the question for many patients: **Does Glyxambi have a generic?** and what are the options for controlling costs in the meantime?

With the market for obesity medications growing rapidly, the high cost of brand-name drugs like Zepbound has many patients asking: how long before Zepbound goes generic? The timeline is governed by a complex web of patent protections and FDA exclusivities that protect the original manufacturer's investment for years.

Approximately 16 million people in the U.S. have been diagnosed with dry eye disease [1.8.4]. For those seeking affordable treatment, a common question is: **Is there a generic version of Tyrvaya?** As of September 2025, the answer is no [1.2.2].

As of late 2025, there is no generic version of Ubrelvy (ubrogepant) available on the market. This means Ubrelvy is currently only available as a brand-name medication, which can influence its cost and accessibility for patients managing acute migraine attacks.

In October 2023, the U.S. Food and Drug Administration (FDA) approved the first generic versions of the targeted cancer therapy Votrient (pazopanib), marking a significant milestone for patients and healthcare providers. This development followed the expiration of key patents, paving the way for more affordable treatment options.

Affecting over 1 billion people worldwide, migraine is a prevalent neurological disorder causing significant disability [1.6.5]. For many, medications like Nurtec ODT offer relief, raising the question: **How long until Nurtec is generic** and more affordable?

The first generic version of Revlimid, known as lenalidomide, was launched in the United States in March 2022 by Teva Pharmaceuticals, marking a significant development for patients needing this expensive medication. This introduction followed a complex series of legal agreements that initially limited the generic's volume and availability.

As of late 2025, there is no generic version of the antiepileptic drug Xcopri (cenobamate) available in the United States. This means patients prescribed this medication must obtain the higher-cost brand-name drug, a situation that often leads to questions about affordability and future options for a generic form of Xcopri.

In the United States, patents are expected to protect semaglutide until at least 2031, delaying any true generic availability. This timeline has fueled public discussion around the high costs and the question, **will there be a generic semaglutide**?